Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
P. Tomasini (Marseille, France). Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the (pneumo) oncologist. International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach

Member's Comments

No comment yet.

Related content which might interest you: Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the radiotherapist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the thoracic surgeon Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective Source: Eur Respir Monogr 2015; 68: 178-185 Year: 2015 Approaches in patients with locally advanced NSCLC: a surgeon's perspective Source: Eur Respir Monogr 2015; 68: 167-177 Year: 2015 Management of early stage lung cancer: a radiation oncologist's perspective Source: Eur Respir Monogr 2015; 68: 148-158 Year: 2015 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Current neoadjuvant/adjuvant treatment for advanced stage lung cancer Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer Year: 2014 Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Year: 2021 Treatment of unresectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Locally advanced and metastatic lung cancer management delay: Tunisian department experience Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy) Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006